| Time to evolve: predicting engineered T cell-associated toxicity with next-generation models E Donnadieu, M Luu, M Alb, B Anliker, S Arcangeli, C Bonini, ... Journal for immunotherapy of cancer 10 (5), 2022 | 28 | 2022 |
| ProstaTrend—a multivariable prognostic RNA expression score for aggressive prostate cancer M Kreuz, DJ Otto, S Fuessel, C Blumert, C Bertram, S Bartsch, D Loeffler, ... European Urology 78 (3), 452-459, 2020 | 20 | 2020 |
| Time 2EVOLVE: predicting efficacy of engineered T-cells–how far is the bench from the bedside? S Guedan, M Luu, D Ammar, P Barbao, C Bonini, P Bousso, CJ Buchholz, ... Journal for Immunotherapy of Cancer 10 (5), 2022 | 18 | 2022 |
| The role of lncRNAs TAPIR-1 and-2 as diagnostic markers and potential therapeutic targets in prostate cancer M Friedrich, K Wiedemann, K Reiche, SH Puppel, G Pfeifer, I Zipfel, ... Cancers 12 (5), 1122, 2020 | 15 | 2020 |
| Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research S Haehnel, K Reiche, D Loeffler, A Horn, C Blumert, SH Puppel, N Kaiser, ... Scientific Reports 9 (1), 19961, 2019 | 11 | 2019 |
| Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma M Rade, N Grieb, R Weiss, J Sia, L Fischer, P Born, A Boldt, S Fricke, ... Nature Cancer, 1-16, 2024 | 5 | 2024 |
| Transcriptional states of CAR-T infusion relate to neurotoxicity–lessons from high-resolution single-cell SOM expression portraying H Loeffler-Wirth, M Rade, A Arakelyan, M Kreuz, M Loeffler, U Koehl, ... Frontiers in immunology 13, 994885, 2022 | 5 | 2022 |
| Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer C Schimmelpfennig, M Rade, S Füssel, D Löffler, C Blumert, C Bertram, ... BMC cancer 23 (1), 575, 2023 | 2 | 2023 |
| RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level S Haehnel, M Rade, N Kaiser, K Reiche, A Horn, D Loeffler, C Blumert, ... FEBS Open bio 12 (2), 480-493, 2022 | 2 | 2022 |
| A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer M Rade, M Kreuz, A Borkowetz, U Sommer, C Blumert, S Füssel, ... Molecular Medicine 30 (1), 19, 2024 | 1 | 2024 |
| A time-resolved meta-analysis of consensus gene expression profiles during human T-cell activation M Rade, S Böhlen, V Neuhaus, D Löffler, C Blumert, M Merz, U Köhl, ... Genome Biology 24 (1), 287, 2023 | 1 | 2023 |
| Biomarker discovery and confirmation using statistical and machine learning approaches in transcriptomics M Rade Dissertation, Leipzig, Universität Leipzig, 2024, 2024 | | 2024 |
| P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma L Fischer, R Weiss, N Grieb, M Rade, P Born, A Boldt, S Fricke, P Franz, ... Clinical Lymphoma Myeloma and Leukemia 23, S37-S38, 2023 | | 2023 |
| Spatial transcriptomics of primary melanoma lesions M Rade, D Loeffler, FP Grosse, A Scholz, C Blumert, K Reiche, M Kunz EXPERIMENTAL DERMATOLOGY 31 (2), E90-E91, 2022 | | 2022 |
| Transcriptional states of CAR-T infusion relate to neurotoxicity H Loeffler-Wirth, M Rade, A Arakelyan, M Kreuz, M Loeffler, U Koehl, ... | | 2022 |
| Time 2EVOLVE: Predicting efficacy of engineered T-cells-how far is the bench from the bedside? S Guedan Carrio, M Luu, D Ammar, P Barbao, C Bonini, P Bousso, ... | | 2022 |
